Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) Stock Short Interest Drops 89.9%

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) saw a significant decrease in short interest in the month of October. As of October 15th, there was short interest totaling 53 shares, a decrease of 89.9% from the September 30th total of 526 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 5,493 shares, the days-to-cover ratio is presently 0.0 days.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group raised Orion OYJ from a “hold” rating to a “strong-buy” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy”.

Orion OYJ Stock Down 1.4%

Shares of OTCMKTS ORINY traded down $0.78 during midday trading on Wednesday, reaching $54.00. The company’s stock had a trading volume of 903 shares, compared to its average volume of 1,242. The stock has a 50 day simple moving average of $47.15 and a 200-day simple moving average of $41.36. The company has a current ratio of 2.64, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $15.24 billion, a price-to-earnings ratio of 22.22 and a beta of 0.07. Orion OYJ has a fifty-two week low of $30.89 and a fifty-two week high of $56.05.

Orion OYJ (OTCMKTS:ORINY) last issued its quarterly earnings results on Wednesday, October 28th. The company reported $0.68 earnings per share (EPS) for the quarter. Orion OYJ had a net margin of 28.52% and a return on equity of 50.37%.

About Orion OYJ

Orion Oyj, also known as Orion Corporation, is a Finnish pharmaceutical company that develops, manufactures and markets human and veterinary medicines. Its portfolio includes prescription medicines, over-the-counter products, generic pharmaceuticals and active pharmaceutical ingredients.

The company focuses on several therapeutic areas, including central nervous system disorders, oncology, respiratory diseases, pain management and veterinary medicine. Orion is particularly recognized for treatments related to Parkinson’s disease, as well as its Easyhaler line of inhaled medicines for respiratory conditions.

Founded in Finland in 1917, Orion is headquartered in Espoo.